| URL | https://www.biopharma-reporter.com/Article/2021/11 |
| Source | BioPharma-Reporter |
| Date Published | 11/30/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | EnGeneIC |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | Outsourced |
| Country(ies) from which reshored: | Australia |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | EnGeneIC Dream Vector (EDV), non-living nanocells |
| What domestic positive factors made reshoring more attractive? | Other, Covid-19 |